The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

Launched by WESTERN SYDNEY LOCAL HEALTH DISTRICT · Mar 26, 2023

Keywords

ClinConnect Summary

This clinical trial, called the Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study, is looking at the long-term effects of different procedures used to remove abnormal growths in the upper digestive system, such as those found in the stomach and esophagus. The study focuses on three specific techniques: Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR), and Submucosal-Tunneling Endoscopic Resection (STER), all aimed at treating larger lesions, or growths, that are over 10mm in size.

To be part of this study, you need to be 18 years or older and have specific types of growths that can be treated with these procedures. Unfortunately, if you are pregnant, unable to provide informed consent, or taking certain blood-thinning medications, you won’t be eligible. If you participate, you can expect to undergo one of these procedures and then be monitored to understand how well it works over time. This trial is currently recruiting participants, and it aims to gather important information that might help improve treatment options for patients with upper gastrointestinal cancers in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • UGI neoplastic lesions \> 10mm
• • Lesions for ESD limited to the mucosal and/or submucosal layer OR
• • Lesions for EFTR limited to the muscularis propria layer OR
• • Lesions for STER limited to the submucosal and/or muscularis propria layer
• • Aged 18 years or older
• Exclusion Criteria:
• • Age less than 18
• • Unable to give informed consent
• • Pregnant or lactating patients
• • Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally